Peptides Targeting Kindlin-1 and Beta-Integrin Interaction

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Cancer cells with high Kindlin-1 expression levels exhibit increased proliferation, migration, and invasion, leading to worse prognosis and metastasis, for which current treatments are inadequate.

Innovation Solution

Development of peptides targeting the interaction between Kindlin-1 and β-integrins, specifically the amino acid sequences SEQ ID NO: 1 (SFLRM) and SEQ ID NO: 14 (QYHISKLSLSAETQDF), which inhibit the activation of β-integrins and reduce cell motility and invasion.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current cancer treatments are used, then general cancer therapy is provided, but they are inadequate for cancers with high Kindlin-1 expression and metastasis

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidtreatment specificity

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent uses peptides (SEQ ID NO: 1 and SEQ ID NO: 14) as intermediary molecules that specifically bind to Kindlin-1, blocking its interaction with β-integrins. This intermediary approach allows selective inhibition of Kindlin-1-mediated processes in cancers with high expression, providing both reliability through targeted mechanism and adaptability through peptide design variations

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent employs peptides with specific amino acid sequences (SFLRM and QYHISKLSLSAETQDF) that are designed to match and bind to the Kindlin-1 binding interface. By changing the molecular parameters of the therapeutic agent from conventional drugs to peptide-based inhibitors with specific sequence properties, the treatment achieves higher specificity for Kindlin-1 overexpressing cancers

Inventive Principle:

Principle #35Parameter changes

2Productivity

If Kindlin-1 expression is high in cancer cells, then cell proliferation and migration increase, but this leads to worse prognosis and metastasis

Engineering Contradiction:

Improvecell proliferation rateVSAvoidmetastasis and invasion

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent applies peptides that preemptively block the Kindlin-1/β-integrin interaction before it can drive malignant processes. By administering the peptide inhibitor, the therapy prevents the harmful effects of Kindlin-1-mediated cell adhesion, migration, and invasion, counteracting the proliferative advantage that Kindlin-1 overexpression provides to cancer cells

Inventive Principle:

Principle #9Preliminary anti-action

Data Source

PatentUS20250163113A1PEPTIDES TARGETING THE INTERACTION BETWEEN KINDLIN-1 AND Beta-INTEGRIN

Publication Date: 2025.05.22 INSTITUT CURIE

AI summary

The present invention concerns novel peptides targeting the interaction between Kindlin-1 and β-integrin, and pharmaceutical compositions comprising these peptides. The invention also relates to these peptides and compositions for use in a method for preventing and/or treated cancer in a subject.